Royalty Pharma Declares Fourth-Quarter 2020 Dividend
The board of directors of Royalty Pharma has approved a dividend of $0.15 per class A share for the fourth quarter of 2020. This dividend is set to be paid on December 15, 2020, to shareholders recorded by the close of business on November 20, 2020. Royalty Pharma is known for being the largest buyer of biopharmaceutical royalties, holding a portfolio that includes royalties on over 45 commercial products from major therapeutics companies.
- Approved dividend of $0.15 per share increases returns for shareholders.
- Stable portfolio of royalties on over 45 commercial products indicates strong cash flow.
- None.
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of
The dividend will be paid on December 15, 2020, to shareholders of record at the close of business on November 20, 2020.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-2295
ir@royaltypharma.com
FAQ
What is the amount of the dividend declared by Royalty Pharma for Q4 2020?
When will the dividend be paid to shareholders?
What is the record date for the dividend payment?
How many commercial products does Royalty Pharma's portfolio include?
